Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Olverembatinib (HQP1351)

HQP1351SJ0003

Ascentage Pharma · Phase 1 · Recruiting · Enrollment 100

NCT03594422

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety
Olverembatinib 30 to 50 mg every other dayn/r

A count stays a count. This page does not turn a count into a percent.